Market Closed -
Nyse
21:00:02 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
38.97
USD
|
+1.12%
|
|
-0.05%
|
-74.33%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Capitalization
1 |
971.8
|
1,615
|
2,844
|
5,137
|
9,027
|
Enterprise Value (EV)
1 |
840.3
|
1,469
|
2,775
|
5,570
|
9,887
|
P/E ratio
|
-5.4
x
|
-6.02
x
|
-4.99
x
|
-6.56
x
|
-10.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
80,742,231
x
|
19,516,872
x
|
EV / Revenue
|
-
|
-
|
-
|
87,534,473
x
|
21,377,123
x
|
EV / EBITDA
|
-7.81
x
|
-6.55
x
|
-5.8
x
|
-8.76
x
|
-14.5
x
|
EV / FCF
|
-15.5
x
|
-11.5
x
|
-12.1
x
|
-10.5
x
|
-26
x
|
FCF Yield
|
-6.44%
|
-8.68%
|
-8.25%
|
-9.52%
|
-3.85%
|
Price to Book
|
7.37
x
|
10.8
x
|
-384
x
|
-13.3
x
|
-12.5
x
|
Nbr of stocks (in thousands)
|
36,018
|
43,683
|
52,240
|
59,939
|
65,501
|
Reference price
2 |
26.98
|
36.98
|
54.44
|
85.71
|
137.8
|
Announcement Date
|
06/03/18
|
28/02/19
|
26/02/20
|
01/03/21
|
25/02/22
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Net sales
|
-
|
-
|
-
|
-
|
63.63
|
462.5
|
EBITDA
1 |
-60.63
|
-107.5
|
-224.3
|
-478.5
|
-635.9
|
-679.6
|
EBIT
1 |
-60.64
|
-107.6
|
-224.6
|
-479.1
|
-645.4
|
-704
|
Operating Margin
|
-
|
-
|
-
|
-
|
-1,014.33%
|
-152.22%
|
Earnings before Tax (EBT)
1 |
-63.44
|
-138.2
|
-240.5
|
-528.4
|
-758.4
|
-843.3
|
Net income
1 |
-63.68
|
-139.2
|
-240.9
|
-528.8
|
-766.8
|
-846.6
|
Net margin
|
-
|
-
|
-
|
-
|
-1,205.14%
|
-183.04%
|
EPS
2 |
-5.050
|
-4.999
|
-6.148
|
-10.91
|
-13.06
|
-13.09
|
Free Cash Flow
1 |
-30.2
|
-54.1
|
-127.5
|
-229
|
-530.2
|
-380.2
|
FCF margin
|
-
|
-
|
-
|
-
|
-833.23%
|
-82.21%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
07/04/17
|
06/03/18
|
28/02/19
|
26/02/20
|
01/03/21
|
25/02/22
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
432
|
860
|
Net Cash position
1 |
18.8
|
131
|
147
|
69
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.6796
x
|
-1.266
x
|
Free Cash Flow
1 |
-30.2
|
-54.1
|
-127
|
-229
|
-530
|
-380
|
ROE (net income / shareholders' equity)
|
18,797%
|
-214%
|
-170%
|
-737%
|
453%
|
167%
|
ROA (Net income/ Total Assets)
|
-262%
|
-77.3%
|
-64.2%
|
-94.4%
|
-78.2%
|
-49.9%
|
Assets
1 |
24.29
|
180
|
375
|
560
|
980.2
|
1,697
|
Book Value Per Share
2 |
-3.440
|
3.660
|
3.410
|
-0.1400
|
-6.460
|
-11.00
|
Cash Flow per Share
2 |
1.800
|
3.650
|
5.980
|
6.050
|
2.190
|
2.570
|
Capex
1 |
0.03
|
0.54
|
4.17
|
3.78
|
3.97
|
1.72
|
Capex / Sales
|
-
|
-
|
-
|
-
|
6.24%
|
0.37%
|
Announcement Date
|
07/04/17
|
06/03/18
|
28/02/19
|
26/02/20
|
01/03/21
|
25/02/22
|
|
1st Jan change
|
Capi.
|
---|
| -74.33% | 541M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|